FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549
---------------	-----------

Check this box if no longer subject	STATEMENT C
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursu

OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Deschatelets Pascal					2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [APLS]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (circle title and content of the content					
(Last)	(Fi	rst) (ř LRMACEUTICA	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/12/2024								X	belov	er (give title v) Chief Scier	ntific	Other (s below)	эресіту П	
100 FIFTH AVENUE, 3RD FLOOR				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) WALTHAM MA 02451													X	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					l_	Rule 10b5-1(c) Transaction Indication													
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																	
		Table	I - N	on-Deriva	tive S	Secui	rities	Acc	quirec	d, Dis	sposed of	, or E	Benefici	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/					if any	emed ion Date, /Day/Year)		3. 4. Securities Acquir Transaction Disposed Of (D) (In: 8)					Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Transa	ransaction(s) nstr. 3 and 4) (Instr.			(Instr. 4)
Common	Stock			02/12/20)24				S ⁽¹⁾		1,148	D	\$67.70	669	1,115,983 D				
		Tal	ble II								osed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e Exer ation D h/Day/		7. Titl Amou Secur Unde Deriv Secur 3 and	int of rities rlying ative rity (Instr. 4)	Der Sec	rice of ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

1. This represents shares sold to cover tax withholding on the Restricted Stock Units released on 02/09/2024.

/s/ David Watson, attorney-infact for Pascal Deschatelets

02/13/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.